Literature DB >> 2933262

Direct effect of interleukin 2 on the differentiation of human B cells which have not been preactivated in vitro.

A S Fauci.   

Abstract

Unfractionated as well as small and large human tonsillar B cells were found to differentiate in the presence of recombinant interleukin 2 (IL2) without requiring an in vitro preactivation signal. These cell suspensions did not contain detectable T cells, monocytes or natural killer cells both at the initiation and the termination of cultures, and did not respond to the T cell-dependent polyclonal B cell activator pokeweed mitogen. They contained very few Tac antigen-bearing cells (less than 2.5%) at the beginning and at the termination of the cultures in the absence of IL2. In the presence of IL2, only a minimal increase in the number of Tac antigen-bearing cells was noted. The observed differentiation was not due to the effects of contaminating T cells, since cultures purposely contaminated with up to 5% of T cells did not contain greater amounts of IgM, IgG or IgA than cultures without T cells added back. Furthermore, when T cells were present at a ratio of 1 T cell per 9 B cells, the production of IgM was decreased. Taken together, these data support the hypothesis that (a) B cell differentiation in response to IL2 may occur in the absence of in vitro preactivation, and in this case cannot be related to the expression of Tac antigen on the B cell surface; (b) it is not due to helper effects of very low numbers of T cells which might contaminate the B cell suspensions; and (c) it most likely results from a direct effect of IL2 on B cells themselves. The data also point out the fact that, in the presence of IL2, T cells may trigger inhibitory effects on IL2-induced B cell differentiation rather than provide helper signals.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933262     DOI: 10.1002/eji.1830151102

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Interleukin 2 receptor expression by human blood lymphocytes after vaccination with pneumococcal polysaccharides.

Authors:  N Tvede; C Heilmann; L D Christensen
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

2.  Activation of resting human B cells by helper T-cell clone supernatant: characterization of a human B-cell-activating factor.

Authors:  A Diu; M L Gougeon; J L Moreau; E L Reinherz; J Thèze
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  Transfection of an immunoglobulin kappa gene into mature human B lymphocytes.

Authors:  L T Bich-Thuy; C Queen
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

4.  Interleukin-2 effects on human B cells activated in vivo.

Authors:  T Miyawaki; T Suzuki; J L Butler; M D Cooper
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

5.  Role of interleukin-2 and interferon-gamma in inducing production of IgG subclasses in lymphocytes of human newborns.

Authors:  Y Kawano; T Noma
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

Review 6.  Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient.

Authors:  S Doi; O Saiki; T Hara; T Sugita; K Ha-Kawa; T Tanaka; H Hara; S Negoro; H Yabuuchi; S Kishimoto
Journal:  Eur J Pediatr       Date:  1989-06       Impact factor: 3.183

7.  Expression of novel interleukin 2 binding molecules and their functional roles in human B cell differentiation.

Authors:  T Tanaka; O Saiki; S Doi; M Suemura; S Negoro; S Kishimoto
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

8.  Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes.

Authors:  J Punnonen; B G Cocks; J M Carballido; B Bennett; D Peterson; G Aversa; J E de Vries
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

9.  Suppression of monocyte and neutrophil function by recombinant IL-2.

Authors:  S E Smith; G D Warren; Y H Thong; J G McCormack
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.